The news: The FDA issued 25 warning letters in June to telehealth providers marketing compounded GLP-1s, citing misleading promotional practices, including claims that products contain the same ingredients as FDA-approved drugs Eli Lilly's tirzepatide and Novo Nordisk's semaglutide
The study tracked over 82,000 diabetes patients between 2014 and 2017
doi: 10.1093/jn/131.9.2515S
Abstract Purpose of Review Glucagon-like peptide- 1 receptor agonists (GLP- 1 RA) are a rapidly expanding class of medications used to treat many chronic diseases
Commonly discussed side effects of semaglutide may include nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite, and indigestion
[177] Clearly, there is a need for new therapies which can increase the efficacy of cancer treatment